Review: Surgical Treatment of Type 2 Diabetes

María Dolores Hellín Gil, Pedro Pujante Alarcón, Alfonso López Ruiz, María Ángeles Ibañez, Alicia Hernández Torres, Ana Belén Hernández Cascales

Community Pharmacy, Bullas (Murcia), Spain.
Endocrinology and Nutrition Service, Hos- pital University Virgen de la Arrixaca de Murcia, Murcia, Spain;.
Health Center Mar- iano Yago, Yecla (Murcia), Spain;.
Infectious Internal Medicine, Hospital University Virgen de la Arrixaca de Murcia, Murcia, Spain..
Nutrition Service, Hospital University Virgen de la Arrixaca de Murcia, Murcia, Spain;.

DOI: 10.4236/pp.2014.51005                

Abstract

In the last decades we have witnessed a significant increase in the incidence of type 2 diabetes mellitus, and obesity in parallel. So 90% of patients with Diabetes Mellitus type 2 (DM2) are obese. Changes in lifestyle (diet and exercise), behavioral therapies or the use of certain anti-obesity drugs have shown a limited effect and are not maintained over time. Currently, bariatric surgery is the most effective anti-obesity treatment, which is durable and resolves associated comorbidities. The surgical treatment of obesity for the modification of the anatomy of the digestive system is to produce gastric capacity constraints alone or associate with varying degrees of intestinal malabsorption and reduce body weight, improve and maintain the comorbidities associated weight loss by reduced food intake alone or in combination with malabsorption of this. The development of these surgical techniques has occurred in stages. With these techniques, setting to bariatric surgery is an effective, safe and proven procedure for the treatment of obesity and its complications especially DM2, as their post surgery referral mechanisms provide us with information for potential therapeutic treatment aimed at optimizing the control DM2 patients metabolic obese. In this review, we expose the evidence in treatment of DM2 with bariatric surgery and the actual hypothesis trying to explain how it is possible.

Keywords

DM2; Bariatric Surgery; Gastric Bypass

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	C. L. Ogden, M. D. Carroll, L. R. Curtin, M. A. McDo-well, C. J. Tabak and K. M. Flegal, “Prevalence of Overweight and Obesity in the United States, 1999-2004,” JAMA, Vol. 295, No. 13, 2006, pp. 1549-1555. http://dx.doi.org/10.1001/jama.295.13.1549
[2]	H. Kolb and T. Mandrup-Poulsen, “The Global Diabetes Epidemic as a Consequence of Lifestyle-Induced Low-Grade Inflammation,” Diabetologia, Vol. 53, No. 1, 2010, pp. 10-20. http://dx.doi.org/10.1007/s00125-009-1573-7
[3]	R. H. Unger, “Minireview: Weapons of Lean Body Mass Destruction: The Role of Ectopic Lipids in the Metabolic Syndrome,” Endocrinology, Vol. 144, No. 12, 2003, pp. 5159-5165. http://dx.doi.org/10.1210/en.2003-0870
[4]	A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda and R. A. DeFronzo, “San Antonio Metabolism Study. Beta-Cell Dysfunction and Glucose Intolerance: Results from the San Antonio Metabolism (SAM) Study,” Diabetología, Vol. 47, No. 1, 2004, pp. 31-39. http://dx.doi.org/10.1007/s00125-003-1263-9
[5]	G. Schernthaner, J. M. Brix, H. P. Kopp and G. H. Schernthaner, “Cure of Type 2 Diabetes by Metabolic Surgery? A Critical Analysis of the Evidence in 2010,” Diabetes Care, Vol. 34, No. 2, 2010, pp. 355S-360S.
[6]	W. J. Pories, K. G. MacDonald Jr., E. J. Morgan, M. K. Sinha, G. L. Dohm, M. S. Swanson, et al., “Surgical Treatment of Obesity and Its Effect on Diabetes: 10-y Follow-Up,” The American Journal of Clinical Nutrition, Vol. 55, No. 2, 1992, pp. 582S-85S.
[7]	C. D. Sjostrom, L. Lissner, H. Wedel and L. Sjostrom, “Reduction in Incidence of Diabetes, Hypertension and Lipid Disturbances after Intentional Weight Loss induced by Bariatric Surgery: The SOS Intervention Study,” Obesity Research, Vol. 7, No. 5, 1999, pp. 477-484. http://dx.doi.org/10.1002/j.1550-8528.1999.tb00436.x
[8]	L. Sjostrom, A. K. Lindroos, M. Peltonen, J. Torgerson, C. Bouchard, B. Carlsson, et al., “Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery,” New England Journal of Medicine, Vol. 351, No. 26, 2004, pp. 2683-2693. http://dx.doi.org/10.1056/NEJMoa035622
[9]	W. J. Pories, “Bariatric Surgery: Risks and Rewards,” Journal of Clinical Endocrinology & Metabolism, Vol. 93, No. 11, 2008, pp. S89-S96. http://dx.doi.org/10.1210/jc.2008-1641
[10]	D. R. Cottam, S. G. Mattar, E. Barinas-Mitchell, et al., “The Chronic Inflammatory Hypothesis for the Morbidity Associated with Morbid Obesity: Implications and Effects of Weight Loss,” Obesity Surgery, Vol. 14, No. 15, 2004, pp. 589-600. http://dx.doi.org/10.1381/096089204323093345
[11]	N. Scopinaro, F. Papadia, G. Camerini, G. Marinari, D. Civalleri and A. Gian Franco, “A Comparison of a Personal Series of Biliopancreatic Diversion and Literature Data on Gastric Bypass Help to Explain the Mechanisms of Resolution of Type 2 Diabetes by the Two Operations,” Obesity Surgery, Vol. 18, No. 8, 2008, pp. 1035-1038. http://dx.doi.org/10.1007/s11695-008-9531-x
[12]	D. S. Hess, D. W. Hess and R. S. Oakley, “The Biliopancreatic Diversion with the Duodenal Switch: Results beyond 10 Years,” Obesity Surgery, Vol. 15, No. 3, 2005, pp. 408-416. http://dx.doi.org/10.1381/0960892053576695
[13]	A. C. Wittgrove and G. W. Clark, “Laparoscopic Gastric Bypass, Roux-en-Y-500 Patients: Technique and Results, with 3 -60 Month Follow-Up,” Obesity Surgery, Vol. 10, No. 3, 2000, pp. 233-239. http://dx.doi.org/10.1381/096089200321643511
[14]	B. Z. A. Moreno, “Cirugía Bariatrica: Situación Actual,” Revista de Medicina de la Universidad de Navarra, Vol. 48, No. 2, 2004, p. 6.
[15]	J. J. Arrizabalaga, A. Calanas-Continente, J. Vidal, et al., “Guía Práctica Clínica Para el Manejo del Sobrepeso y la Obesidad en Personas Adultas,” Endocnologia y Nutrición, Vol. 50, Suppl. 4, 2003, pp. 1-38.
[16]	H. Buchwald, Y. Avidor, E. Braunwald, M. D. Jensen, W. Pories, K. Fahrbach, et al., “Bariatric Surgery: A Systematic Review and Meta-Analysis,” JAMA, Vol. 292, No. 14, 2004, pp. 1724-1737. http://dx.doi.org/10.1001/jama.292.14.1724
[17]	L. Sjostrom, K. Narbro, C. D. Sjostrom, K. Karason, B. Larsson, H. Wedel, et al., “Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects,” New England Journal of Medicine, Vol. 357, No. 8, 2007, pp. 741-752. http://dx.doi.org/10.1056/NEJMoa066254
[18]	P. R. Schauer, B. Burguera, S. Ikramuddin, D. Cottam, W. Gourash, G. Hamad, et al., “Effect of Laparoscopic Rouxen Y Gastric Bypass on Type 2 Diabetes Mellitus,” Annals of Surgery, Vol. 238, No. 4, 2003, pp. 467-484.
[19]	J. A. Tadross and C. W. le Roux, “The Mechanisms of Weight Loss after Bariatric Surgery,” International Journal of Obesity (London), Vol. 33, Suppl. 1, 2009, pp. S28-S32. http://dx.doi.org/10.1038/ijo.2009.14
[20]	D. E. Cummings, J. Overduin and K. E. Foster-Schubert, “Gastric Bypass for Obesity: Mechanisms of Weight Loss and Diabetes Resolution,” Journal of Clinical Endocrinology & Metabolism, Vol. 89, No. 6, 2004, pp. 2608-2615. http://dx.doi.org/10.1210/jc.2004-0433
[21]	D. S. Tichansky, J. D. Boughter Jr. and A. K. Madan, “Taste Change after Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Adjustable Gastric Banding,” Surgery for Obesity and Related Diseases, Vol. 2, No. 4, 2006, pp. 440-444. http://dx.doi.org/10.1016/j.soard.2006.02.014
[22]	D. E. Cummings, D. S. Weigle, R. S. Frayo, P. A. Breen, M. K. Ma, E. P. Dellinger, et al., “Plasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery,” New England Journal of Medicine, Vol. 346, No. 21, 2002, pp. 1623-1630. http://dx.doi.org/10.1056/NEJMoa012908
[23]	J. Korner, M. Bessler, L. J. Cirilo, I. M. Conwell, A. Daud, N. L. Restuccia, et al., “Effects of Roux-en-Y Gastric Bypass Surgery on Fasting and Postprandial Concentrations of Plasma Ghrelin, Peptide YY, and Insulin,” Journal of Clinical Endocrinology & Metabolism, Vol. 90, No. 1, 2005, pp. 359-365. http://dx.doi.org/10.1210/jc.2004-1076
[24]	W. J. Pories, M. S. Swanson, K. G. MacDonald, S. B. Long, P. G. Morris, B. M. Brown, et al., “Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult-Onset Diabetes Mellitus,” Annals of Surgery, Vol. 222, No. 3, 1995, pp. 339-350. http://dx.doi.org/10.1097/00000658-199509000-00011
[25]	D. E. Cummings, “Endocrine Mechanisms Mediating Remission of Diabetes after Gastric Bypass Surgery,” International Journal of Obesity (London), Vol. 33, Suppl. 1, 2009, pp. S33-S40. http://dx.doi.org/10.1038/ijo.2009.15
[26]	S. R. Chipkin and R. J. Goldberg, “Obesity Surgery and Diabetes: Does a Chance to Cut Mean a Chance to Cure?” American Journal of Medicine, Vol. 122, No. 3, 2009, pp. 205-206.
[27]	M. Hempen, H. P. Kopp, M. Elhenicky, et al., “YKL-40 Is Elevated in Morbidly Obese Patients and Declines after Weight Loss,” Obesity Surgery, Vol. 19, No. 11, 2009, pp. 1557-1563. http://dx.doi.org/10.1007/s11695-009-9917-4
[28]	C. W. le Roux, S. J. Aylwin, R. L. Batterham, C. M. Borg, F. Coyle, V. Prasad, et al., “Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters,” Annals of Surgery, Vol. 243, No. 1, 2006, pp. 108-114. http://dx.doi.org/10.1097/01.sla.0000183349.16877.84
[29]	J. Korner, M. Bessler, W. Inabnet, C. Taveras and J. J. Holst, “Exaggerated Glucagon-Like Peptide-1 and Blunted Glucose-Dependent Insulinotropic Peptide Secretion Are Associated with Roux-en-Y Gastric Bypass but Not Adjustable Gastric Banding,” Surgery for Obesity and Related Diseases, Vol. 3, No. 6, 2007, pp. 597-601. http://dx.doi.org/10.1016/j.soard.2007.08.004
[30]	J. M. Isbell, R. A. Tamboli, E. N. Hansen, et al., “The Importance of Caloric Restriction in the Early Improvements in Insulin Sensitivity Following Roux-en-Y Gastric Bypass Surgery,” Diabetes Care, Vol. 33, No. 7, 2010, pp. 1438-1442. http://dx.doi.org/10.2337/dc09-2107
[31]	F. Rubino, A. Forgione, D. E. Cummings, M. Vix, D. Gnuli, G. Mingrone, et al., “The Mechanism of Diabetes Control after Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the Pathophysiology of Type 2 Diabetes,” Annals of Surgery, Vol. 244, No. 5, 2006, pp. 741-749. http://dx.doi.org/10.1097/01.sla.0000224726.61448.1b
[32]	M. J. Perley and D. M. Kipnis, “Plasma Insulin Responses to Oral and Intravenous Glucose: Studies in Normal and Diabetic Sujbjects,” Journal of Clinical Investigation, Vol. 46, No. 12, 1967, pp. 1954-1962. http://dx.doi.org/10.1172/JCI105685
[33]	M. Nauck, F. Stockmann, R. Ebert and W. Creutzfeldt, “Reduced Incretin Effect in Type 2 (Non-Insulin-Dependent) Diabetes,” Diabetologia, Vol. 29, No. 1, 1986, pp. 46-52. http://dx.doi.org/10.1007/BF02427280
[34]	M. A. Nauck, N. Kleine, C. Orskov, J. J. Holst, B. Willms and W. Creutzfeldt, “Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients,” Diabetologia, Vol. 36, No. 8, 1993, pp. 741-744. http://dx.doi.org/10.1007/BF00401145
[35]	C. Guidone, M. Manco, E. Valera-Mora, A. Iaconelli, D. Gniuli, A. Mari, et al., “Mechanisms of Recovery from Type 2 Diabetes after Malabsorptive Bariatric Surgery,” Diabetes, Vol. 55, No. 7, 2006, pp. 2025-2031. http://dx.doi.org/10.2337/db06-0068
[36]	D. J. Pournaras, A. Osborne, S. C. Hawkins, et al., “The Gut Hormone Response Following Roux-em-Y Gastric Bypass: Cross-Sectional and Prospective Study,” Obesity Surgery, Vol. 20, No. 1, 2010, pp. 56-60. http://dx.doi.org/10.1007/s11695-009-9989-1
[37]	A. Keidar, “Bariatric Surgery for Type 2 Diabetes Reversal: The Risks,” Diabetes Care, Vol. 34, No. 2, 2011, pp. 361S-366S.
[38]	T. D. Adams, A. M. Stroup, R. E. Gress, et al., “Cancer Incidence and Mortality after Gastric Bypass Surgery,” Obesity, Vol. 17, No. 4, 2009, pp. 796-802. http://dx.doi.org/10.1038/oby.2008.610